Humacyte (NASDAQ:HUMA) Shares Cross Below Fifty Day Moving Average – Here’s What Happened

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report)’s share price passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $0.49 and traded as low as $0.4444. Humacyte shares last traded at $0.4450, with a volume of 5,769,439 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on HUMA shares. Benchmark cut their price objective on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. Williams Trading set a $1.00 target price on Humacyte in a research report on Friday, October 16th. Wall Street Zen upgraded Humacyte to a “sell” rating in a research note on Saturday, November 14th. Cantor Fitzgerald set a $1.00 target price on Humacyte in a research note on Thursday, November 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.48.

View Our Latest Analysis on Humacyte

Humacyte Stock Down 18.0%

The firm has a market cap of $123.62 million, a price-to-earnings ratio of -1.01 and a beta of 2.64. The company has a debt-to-equity ratio of 3.65, a current ratio of 3.34 and a quick ratio of 3.11. The stock has a 50-day moving average of $0.49 and a 200-day moving average of $0.77.

Institutional Trading of Humacyte

A number of institutional investors have recently modified their holdings of the stock. Beacon Pointe Advisors LLC bought a new stake in Humacyte during the second quarter worth about $28,000. Bank of New York Mellon Corp bought a new position in Humacyte in the 2nd quarter valued at about $44,000. Sei Investments Co. bought a new position in Humacyte in the 1st quarter valued at about $56,000. Empowered Funds LLC bought a new position in Humacyte in the 3rd quarter valued at about $81,000. Finally, Miramontes Capital LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at approximately $85,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Featured Stories

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.